BMO Capital analyst John Joyner downgrades Trane Technologies (NYSE:TT) from Outperform to Market Perform and announces $180 price target.
Annexon’s Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study
Annexon Inc (NASDAQ:ANNX) announced topline results from its ARCHER Phase 2 trial of ANX007 in patients with geographic atrophy (GA).…